Aileron Therapeutics, a US-based biopharmaceutical company that is developing therapeutics based on its stapled peptide drug platform, has secured $30m in series E equity financing from existing investors including Roche Venture Fund, the corporate venturing unit of Switzerland-based Roche, Novartis Venture Funds, the corporate venturing unit of Switzerland-based pharmaceutical company Novartis, Lilly Ventures, the corporate venturing affiliate of US-based pharmaceutical company Eli Lilly and Company, SR One, the corporate venturing division of pharmaceutical company GlaxoSmithKline, and venture capital firms Apple…